The Pivotal Protocol
Operator Note No. XXII

When you inject matters.

Biology runs on clocks. GH secretagogues administered at the wrong time of day blunt half the signal. Tissue repair peptides compete with fed-state inflammation cascades. Getting the timing architecture right is not optimization theater. It is basic pharmacology.

Operator Note XXII Circadian Pharmacology May 2026

I. Circadian biology primer.

The circadian clock is a 24-hour molecular oscillator present in virtually every cell. It is governed by the CLOCK/BMAL1 transcription factor complex, which drives transcription of the Period (PER) and Cryptochrome (CRY) genes. PER and CRY proteins accumulate, then suppress CLOCK/BMAL1 activity, completing a roughly 24-hour feedback loop. This is not a curiosity of chronobiology: it means every tissue has a time-of-day context for every signal it receives. verified [I]

Growth hormone follows a pulsatile, sleep-entrained secretion pattern. The dominant GH pulse occurs 60 to 90 minutes after sleep onset, during slow-wave sleep (SWS). This single pulse accounts for approximately 70% of total daily GH secretion in healthy adults. verified [IV]

Cortisol peaks within 30 to 45 minutes of waking: the cortisol awakening response (CAR). Testosterone in men peaks in early morning, typically between 6 and 8 AM. Melatonin begins rising approximately 2 hours before habitual sleep onset and is suppressed by morning light. Insulin sensitivity is highest in the morning and declines through the afternoon as tissue responsiveness to insulin diminishes. Each of these rhythms creates a window. Peptide administration either aligns with that window or works against it.

II. GH secretagogue timing.

CJC-1295 and ipamorelin are most effective administered at bedtime, specifically 30 to 60 minutes before sleep, to amplify the natural SWS-coincident GH pulse. This is the primary timing rule for this compound class. It is not a preference. It is a pharmacodynamic requirement.

Administering GH secretagogues in the morning produces a GH pulse against a background of rising cortisol and insulin. Both suppress GH signaling at the receptor and post-receptor level. Bedtime administration aligns with the physiological window when somatostatin tone is lowest and GHRH sensitivity is highest. This is not optional detail.

Daytime protocols using twice-daily dosing: the secondary daytime injection is optimally placed in the late afternoon, between 4 and 6 PM, at a minimum of 2 hours after the last carbohydrate-containing meal. Postprandial insulin blunts GH release acutely. This is not a minor effect: a carbohydrate-rich meal 60 minutes before injection can reduce GH pulse amplitude by 50% or more. inferred from insulin/GH suppression literature

Fasted administration: GH pulse amplitude is significantly higher in the fasted state. A 3-hour fast before injection is standard for the secondary daytime dose. Water is fine. Coffee without caloric additives is fine. Any caloric intake restarts the insulin response clock.

III. Tissue repair peptide timing.

BPC-157 and TB-500 do not have strict circadian timing requirements in the published literature. Their mechanisms: BPC-157 acts on the nitric oxide system, promotes angiogenesis, and modulates growth factor signaling. TB-500 (thymosin beta-4) sequesters actin monomers and promotes cell migration and tissue remodeling. Neither mechanism has a well-characterized circadian preference. verified

However, mechanistic considerations favor fasted administration for both. Feeding activates mTOR signaling and triggers a low-grade inflammatory cascade associated with digestion and metabolic processing. BPC-157's anti-inflammatory effects may be partially counteracted by postprandial inflammatory tone. Morning administration upon waking, before the first meal, is the rational choice for repair peptides targeting musculoskeletal injury.

For TB-500 specifically: the actin sequestration and cell migration activity are not time-dependent. Consistent timing across the dosing schedule (typically twice weekly) carries more clinical weight than the specific window. Pick a time. Use it every injection.

IV. Cognitive peptide timing.

Semax (the ACTH(4-10) heptapeptide analog) upregulates BDNF expression. BDNF expression in rodent models peaks in the late morning portion of the active phase. Morning administration, fasted or with a light protein meal, is the preferred clinical window. The neurotrophin response is highest when cortisol is declining from its morning peak and baseline catecholamine tone is elevated. verified [V]

Selank functions as an anxiolytic companion to Semax, primarily through GABAergic and enkephalin-related mechanisms. These effects are not strongly circadian-dependent. Morning administration is preferred for a practical reason: it reduces the probability of interfering with sleep architecture for patients who are sensitive to the mild stimulant character of combined Semax and Selank.

The Evening Administration Problem

Cognitive peptides administered in the evening carry a measurable risk of disrupting sleep architecture in sensitive patients. Semax in particular has been reported by patients to increase alertness and delay sleep onset when administered after 4 PM. Morning or early afternoon is the appropriate window. Administering activating peptides at night and then wondering why sleep quality is poor is a clinical error. Clinicians who do not specify a timing window for cognitive peptides are prescribing incompletely. The omission is not neutral: it transfers the burden of discovery to the patient, at the cost of sleep quality.

V. Longevity peptide timing.

Epithalon: the Soviet clinical literature administered Epithalon in the morning, during a 10-day course. The mechanistic rationale points toward pineal axis responsiveness, which is highest in the early part of the active phase before melatonin onset. Morning is the established and rational window. inferred from Soviet clinical protocols

NAD+ precursors (NMN, NR): morning administration aligns with the SIRT1 circadian peak and the metabolic active phase. Evening NAD+ supplementation may mildly perturb sleep in some individuals via sirtuin-driven energetic activation, a documented though not universal effect. Morning is the low-risk, high-signal window. inferred from sirtuin circadian literature

GHK-Cu: no established circadian preference in the literature. Consistent daily timing is the relevant variable. Pair it with the morning fasted window as the default.

MOTS-c and SS-31: pre-exercise administration, 30 to 60 minutes before activity, creates the highest-signal pharmacodynamic context. MOTS-c acts on AMPK and mitochondrial biogenesis pathways. The exercise stimulus and the peptide signal compound. If the patient is not exercising that day, morning fasted administration is appropriate.

VI. The master timing architecture.

A complete multi-compound protocol without a timing architecture is an incomplete protocol. Clinicians who hand patients a compound list without a daily administration schedule have not finished the prescription. The timing is part of the pharmacology.

The complete daily timing architecture for a full Pivotal protocol stack:

Morning, fasted (on waking)
Semax, Selank, NAD+ precursors, GHK-Cu, MOTS-c (if exercising within 60 minutes), BPC-157 (injury repair)
Pre-exercise (30 to 60 min before)
MOTS-c, SS-31, BPC-157 (if managing training-related injury and not already dosed at waking)
Afternoon (4 to 6 PM, fasted 2+ hours)
Secondary GH secretagogue dose if twice-daily protocol is indicated
Bedtime (30 to 60 min before sleep)
Primary GH secretagogue dose: CJC-1295 plus ipamorelin. Melatonin if pineal axis support is included in the protocol.
Epithalon course
Morning, consistent start time across the 10-day course. Not concurrent with morning stimulating peptides where possible.
Testosterone (injectable)
Consistent day of the week carries more weight than time of day. Split-dose protocols: maintain a strict 3.5-day interval to minimize trough depth.

The single most common timing error in peptide protocols is morning GH secretagogue administration. The second most common is evening cognitive peptide administration. Both are avoidable with a one-page timing sheet given to the patient at the start of the protocol. That sheet should be part of every consult, without exception.

References

  1. Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science. 2010;330(6009):1349-1354. CLOCK/BMAL1 mechanism, peripheral oscillators, metabolic circadian coupling. verified
  2. Van Cauter E, Leproult R, Plat L. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA. 2000;284(7):861-868. GH pulsatility, SWS relationship, sleep architecture coupling. verified
  3. Cedernaes J, Waldeck N, Bass J. Neurogenetic basis for circadian regulation of metabolism by the hypothalamus. Genes Dev. 2019;33(17-18):1136-1158. Circadian feeding circuits and AgRP neuron regulation. verified
  4. Czeisler CA, Weitzman E, Moore-Ede MC, Zimmerman JC, Knauer RS. Human sleep: its duration and organization depend on its circadian phase. Science. 1980;210(4475):1264-1267. SWS timing and the dominant nocturnal GH pulse. verified
  5. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. J Neurochem. 2006;97(Suppl 1):82-86. Semax BDNF upregulation mechanism. verified

THE PIVOTAL PROTOCOL is an intelligence and education layer, not a prescriber. The timing frameworks described here are derived from the cited literature and from Pivotal's protocol design history. Every clinical decision belongs to a licensed physician with full knowledge of the case. A timing sheet does not replace a physician consult. It supplements one.

Apply this to your protocol
Begin a conversation.
Pivotal is by invitation. Submit a brief intake. We respond personally within 24 to 48 hours.
Begin IntakeRead More Notes